CDXS Codexis, Inc. - Common Stock
NASDAQ · Life Sciences Tools & Services · SEC EDGAR'da Görüntüle ↗ kapat Eki 2, 2026 10-K/10-Q Ağu 11, 2026
$1,36
· 52 haftalık aralığın %'i
· düşüğün üstünde
· yükseğe
$0,9652 haftanın en düşüğü
$2,9852 haftanın en yükseği
Piyasa Değeri (MRQ)
$124M
P/E (TTM)
-4.2
Hisse Başına Kâr (TTM)
$-0.32
Gelir (TTM)
$78M
rozetleriniz
52 Haftlık Aralık
$1–$3
Analist Derecelendirmesi
BUY
Fiyat Hedefi
$6
P/E
-4.2
ROE
-69.4%
Net Kâr Marjı
-39.6%
Rozet şeridiniz boş — bu sayfada herhangi bir metriği sabitleyin.
CDXS Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$1.36
Piyasa Değeri (MRQ)
$124M
P/E (TTM)
-4.2
Hisse Başına Kâr (TTM)
$-0.32
Gelir (TTM)
$78M
ROE (TTM)
-69.4%
D/E Borç/Özsermaye (MRQ)
1.2
52 Haftlık Aralık
$1–$3
CDXS Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
aralık
çubuklar
Çubuk çözünürlüğü seçilen döneme uyum sağlar — bir çubuk için açılış/yüksek/düşük/kapanış değerlerini görmek için grafiğin üzerine gelin.
Codexis, Inc. - Common Stock Hakkında Wikipedia'dan şirket genel bakışı
Codexis, Inc. is a protein engineering company that develops enzymes for pharmaceutical, food and medical applications.
History
Codexis is based in Redwood City, CA and was incorporated in 2002. It went public in April 2010 on NASDAQ, and in October, acquired Maxygen's MolecularBreeding technology portfolio.
Pharmaceutical
Codexis won the Presidential Green Chemistry Challenge Award from the U.S. Environmental Protection Agency (EPA) in 2006 for its work on a building block of Lipitor. It then won a second time in 2010 for its work with Merck & Co. on the active ingredient in Januvia.
Nutrition
In 2017, the company entered a partnership with Tate & Lyle to provide research and development for the production of new ingredients. That same year, Codexis announced a collaboration with Nestle to provide enzymes for metabolic disorders.
Biotherapeutics
In 2017, Codexis developed a recombinant phenylalanine ammonia-lyase (PAL) enzyme, to act as a substitute phenylalanine hydroxylase (PAH) enzyme for people who suffer from phenylketonuria. The enzyme was in-licensed by Nestle Health Sciences.
In 2020, Takeda Pharmaceutical announced a collaboration with Codexis to research and create gene therapies for rare diseases, including lysosomal storage disorders.
Life science
In June 2020, they announced a partnership with Molecular Assemblies to engineer enzymes for DNA synthesis.
Technology
Codexis uses directed evolution to develop its enzymes. Using this method, scientists genetically engineer genes, then screen the enzymes produced to see if it creates the properties needed for a specific reaction. Their protein engineering platform, called CodeEvolver, uses machine learning and high-throughput experimentation to learn protein sequence changes and their impacts on protein function.
Kaynak: Wikipedia (İngilizce), CC BY-SA 4.0 · Wikipedia'da Görüntüle ↗
sektörHealthcare
endüstriLife Sciences Tools & Services
çalışanlar146
ülkeUS
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir$70M2016-12-31 → 2025-12-31
Hisse Başına Kâr$-0.502019-12-31 → 2025-12-31
Serbest Nakit Akışı$-24M2016-12-31 → 2025-12-31
Net kar marjı-39.6%2016-12-31 → 2025-12-31
Değerleme ve Oranlar
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
| Metrik | 5 Yıllık trend | CDXS | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| P/E (TTM) | -4.25Y ort. ≈-23.0 | ≈-23.0 | · | · | |
| F/S (TTM) | 1.65Y ort. ≈6.7 | ≈6.7 | 4.2 | Düşük değerli | |
| F/D (MRQ) | 3.85Y ort. ≈5.1 | ≈5.1 | 0.9 | Aşırı değerli | |
| EV / EBITDA (TTM) | -4.9 | · | · | · | |
| Fiyat / Serbest Nakit Akışı (TTM) | -10.25Y ort. ≈2.7 | ≈2.7 | · | · | |
| Fiyat / Nakit Akışı (TTM) | -11.95Y ort. ≈-27.0 | ≈-27.0 | · | · | |
| EV / Gelir (TTM) | 1.4 | · | · | · | |
| EV / FCF (TTM) | -9.1 | · | · | · | |
| Price / Tangible Book (Fiyat / Maddi Defter Değeri) | 2.65Y ort. ≈5.3 | ≈5.3 | · | · |
Akran ortalaması, metrik başına standartlaştırılmış bir temelde hesaplanır ve bu hisse senedi için gösterilen TTM/MRQ temelini her zaman eşleşmeyebilir.
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
| Metrik | 5 Yıllık trend | CDXS | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Faaliyet Kâr Marjı (TTM) | -35.6%5Y ort. ≈-60.4% | ≈-60.4% | -140.7% | En üst düzey | |
| FAVÖK Marjı (TTM) | -28.9%5Y ort. ≈-57.2% | ≈-57.2% | -140.7% | En üst düzey | |
| Vergi Öncesi Kar Marjı (TTM) | -39.5%5Y ort. ≈-65.0% | ≈-65.0% | -122.0% | En üst düzey | |
| Net Kâr Marjı (TTM) | -39.6%5Y ort. ≈-65.1% | ≈-65.1% | -140.9% | En üst düzey | |
| ROA (TTM) | -23.8%5Y ort. ≈-27.5% | ≈-27.5% | -22.2% | Zayıf | |
| ROE (TTM) | -69.4%5Y ort. ≈-59.3% | ≈-59.3% | -34.9% | Zayıf | |
| ROIC | -46.1%5Y ort. ≈-44.8% | ≈-44.8% | -40.5% | Zayıf |
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
| Metrik | 5 Yıllık trend | CDXS | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Borç / Öz Sermaye (MRQ) | 1.2 | · | · | · | |
| Cari Oran (MRQ) | 3.15Y ort. ≈3.8 | ≈3.8 | 6.5 | Düşük likidite | |
| Quick Ratio (Cari Oran) | 3.15Y ort. ≈3.1 | ≈3.1 | 1.8 | Güçlü likidite | |
| Uzun Vadeli Borç / Özkaynak (MRQ) | 1.0 | · | · | · |
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
| Metrik | 5 Yıllık trend | CDXS | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Revenue YoY (Gelir Yıllık Bazda) | 18.6%5Y ort. ≈7.6% | ≈7.6% | · | · | |
| Revenue CAGR 3Y (Gelir 3 Yıllık Bileşik Büyüme Oranı) | -20.2%5Y ort. ≈-12.3% | ≈-12.3% | · | · | |
| Revenue CAGR 5Y (Gelir 5 Yıllık Bileşik Büyüme Oranı) | 0.38% | · | · | · |
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
| Metrik | 5 Yıllık trend | CDXS | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Asset Turnover (Aktif Devir Hızı) | 0.55Y ort. ≈0.5 | ≈0.5 | 0.4 | En üst düzey | |
| Inventory Turnover (Stok Devir Hızı) | 5.25Y ort. ≈12.5 | ≈12.5 | 1.9 | En üst düzey | |
| Revenue / Employee (Çalışan Başına Gelir) | ≈$482.1K | · | · | · |
değer · ≈ 5Y ort. · sektör ortalaması · ortalamaya göre değerlendirme
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
15.7%
Sonraki Rapor
Kas 04, 2026
| Dönem | Rapor | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|---|
| 30 Haziran 2026 | Ağu 11, 2026 | $-0.13 | $-0.14 | 7.7% |
| 31 Mart 2026 | May 12, 2026 | $-0.10 | $-0.14 | 28.3% |
| 31 Aralık 2025 | $0.11 | $-0.04 | 357.0% | |
| 30 Eylül 2025 | $-0.22 | $-0.15 | -45.2% | |
| 30 Haziran 2025 | $-0.16 | $-0.19 | 16.8% | |
| 31 Mart 2025 | $-0.25 | $-0.24 | -3.3% | |
| 31 Aralık 2024 | $-0.13 | $-0.04 | -251.4% |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $70M | $59M | $70M | $139M | $105M | $69M | $68M | $61M | $50M | $49M | $42M | $35M | |
| Cost of Revenue | $9M | $16M | $13M | $38M | $22M | $14M | $16M | $13M | $14M | $10M | $7M | $10M | |
| R&D Expense | $52M | $46M | $59M | $80M | $56M | $44M | $34M | $30M | $30M | $22M | $21M | $23M | |
| SG&A Expense | $47M | $55M | $53M | $52M | $49M | $35M | $32M | $29M | $29M | $25M | $22M | $22M | |
| Operating Expenses | $112M | $118M | $138M | $173M | $127M | $93M | $81M | $72M | $73M | $57M | $50M | $54M | |
| Operating Income | $-42M | $-59M | $-68M | $-35M | $-23M | $-24M | $-13M | $-11M | $-23M | $-9M | $-8M | $-19M | |
| Interest Income | $3M | $4M | $4M | $1M | $459.0K | $405.0K | $1M | $671.0K | $147.0K | $60.0K | $19.0K | $18.0K | |
| Other Non-op | $-5M | $-10M | $-12M | $124.0K | $1M | $-156.0K | $-656.0K | $-291.0K | $-92.0K | $-94.0K | · | · | |
| Pretax Income | $-44M | $-65M | $-76M | $-33M | $-21M | $-24M | $-12M | $-11M | $-23M | $-9M | $-8M | $-19M | |
| Income Tax | $47.0K | $34.0K | $69.0K | $276.0K | $189.0K | $339.0K | $17.0K | $-37.0K | $81.0K | $-40.0K | $-338.0K | $-256.0K | |
| Net Income | $-44M | $-65M | $-76M | $-34M | $-21M | $-24M | $-12M | $-11M | $-23M | $-9M | $-8M | $-19M | |
| EPS (Basic) | $-0.50 | $-0.89 | $-1.12 | $-0.51 | $-0.33 | $-0.40 | $-0.21 | · | · | · | · | · | |
| EPS (Diluted) | $-0.50 | $-0.89 | $-1.12 | $-0.51 | $-0.33 | $-0.40 | $-0.21 | · | · | · | · | · | |
| Shares (Basic) | 87,142,000 | 73,408,000 | 68,131,000 | 65,344,000 | 64,568,000 | 59,360,000 | 56,525,000 | · | · | · | · | · | |
| Shares (Diluted) | 87,142,000 | 73,408,000 | 68,131,000 | 65,344,000 | 64,568,000 | 59,360,000 | 56,525,000 | · | · | · | · | · | |
| EBITDA | $-36M | $-54M | $-68M | $-35M | $-23M | $-24M | $-13M | $-11M | $-23M | $-9M | $-8M | $-19M |
Bilanço
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $51M | $19M | $65M | $114M | $117M | $149M | $90M | $53M | $31M | $19M | $23M | $26M | |
| Short-term Investments | $27M | $54M | $0 | · | · | · | · | · | · | · | · | · | |
| Receivables | · | · | $10M | $32M | $25M | $14M | $9M | $12M | $11M | $6M | $7M | $4M | |
| Inventory | $2M | $2M | $3M | $2M | $1M | $964.0K | $371.0K | $589.0K | $1M | $825.0K | $992.0K | $1M | |
| Prepaid Expense | $6M | $4M | $5M | $5M | $6M | $3M | $3M | $1M | $984.0K | $1M | $1M | $1M | |
| Other Current Assets | $500.0K | $500.0K | $600.0K | $700.0K | · | · | · | · | · | · | · | · | |
| Current Assets | $97M | $99M | $93M | $163M | $162M | $184M | $114M | $68M | $45M | $27M | $33M | $33M | |
| PP&E (Net) | $13M | $14M | $15M | $23M | $21M | $10M | $6M | $5M | $3M | $2M | $3M | $4M | |
| PP&E (Gross) | $58M | $55M | $55M | $62M | $57M | $43M | $40M | $38M | $35M | $34M | $35M | $37M | |
| Accum. Depreciation | $45M | $41M | $39M | $40M | $36M | $33M | $33M | $33M | $32M | $32M | $32M | $31M | |
| Goodwill | $2M | $2M | $2M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | |
| Intangibles | · | · | · | · | · | · | · | · | · | $0 | $3M | $6M | |
| Other Non-current Assets | $883.0K | $1M | $1M | $350.0K | $276.0K | $294.0K | $178.0K | $1M | $302.0K | $259.0K | $310.0K | $294.0K | |
| Total Assets | $148M | $149M | $137M | $250M | $246M | $222M | $149M | $79M | $54M | $36M | $45M | $48M | |
| Accounts Payable | $2M | $3M | $6M | $3M | $3M | $3M | $3M | $3M | $4M | $4M | $3M | $5M | |
| Accrued Liabilities | $3M | $6M | $5M | $15M | $13M | $10M | $7M | $5M | $4M | $2M | $2M | $3M | |
| Current Liabilities | $25M | $24M | $36M | $49M | $33M | $25M | $15M | $18M | $25M | $12M | $15M | $14M | |
| Capital Leases | $30M | $28M | $12M | $38M | $44M | $22M | $25M | $61.0K | $302.0K | · | · | · | |
| Other Non-current Liabilities | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $2M | $2M | $2M | $3M | |
| Total Liabilities | $97M | $82M | $50M | $106M | $82M | $52M | $44M | $23M | $29M | $17M | $22M | · | |
| Long-term Debt | $40M | $29M | · | · | · | · | · | · | · | · | · | · | |
| Total Debt | $40M | $29M | · | · | · | · | · | · | $302.0K | · | · | · | |
| Common Stock | $9.0K | $8.0K | $7.0K | $6.0K | $6.0K | $6.0K | $6.0K | $5.0K | $5.0K | $4.0K | $4.0K | $4.0K | |
| Paid-in Capital | $657M | $630M | $584M | $566M | $552M | $537M | $448M | $387M | $340M | $311M | $306M | $302M | |
| Retained Earnings | $-607M | $-563M | $-498M | $-421M | $-388M | $-366M | $-342M | $-330M | $-315M | $-292M | $-284M | $-276M | |
| AOCI | $8.0K | $52.0K | $0 | · | · | · | · | $0 | $-472.0K | $0 | $405.0K | $-142.0K | |
| Stockholders' Equity | $51M | $67M | $87M | $145M | $164M | $170M | $106M | $56M | $25M | $19M | $23M | $26M | |
| Liabilities + Equity | $148M | $149M | $137M | $250M | $246M | $222M | $149M | $79M | $54M | $36M | $45M | $48M | |
| Shares Outstanding | 90,478,000 | 81,850,000 | 69,905,000 | 65,811,000 | 65,109,000 | 64,283,000 | 58,877,000 | 54,065,000 | 48,365,000 | 41,255,000 | 40,343,000 | 39,563,000 |
Nakit Akışı
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $5M | $5M | $6M | $5M | · | · | · | · | · | · | · | · | |
| Stock-based Comp | $10M | $13M | $10M | $15M | $12M | $8M | $7M | $8M | $7M | $6M | $5M | $5M | |
| Deferred Tax | $-3.0K | $-2.0K | $0 | $-7.0K | $-9.0K | $-8.0K | $-6.0K | $-29.0K | $12.0K | $-31.0K | $-330.0K | $110.0K | |
| Amort. of Intangibles | · | · | · | · | · | · | · | $0 | $0 | $3M | $3M | $3M | |
| Restructuring | $3M | $0 | $3M | $3M | $0 | $0 | · | · | · | · | · | · | |
| Other Non-cash | $10M | $-2M | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-19M | $-49M | $-53M | $11M | $-14M | $-16M | $-13M | $-14M | $-9M | $-2M | $-433.0K | $321.0K | |
| CapEx | $4M | $4M | $4M | $8M | $14M | $4M | $4M | $3M | $985.0K | $888.0K | $1M | $302.0K | |
| Investing Cash Flow | $24M | $-57M | $-5M | $-14M | $-21M | $-6M | $-4M | $-3M | $-983.0K | $-846.0K | $-1M | $5M | |
| Debt Issued | $10M | $30M | $0 | $0 | · | · | · | · | · | · | · | · | |
| Net Debt Issued | $10M | $30M | · | · | · | · | · | · | · | · | · | · | |
| Stock Issued | $17M | $31M | $9M | $0 | $0 | $86M | $0 | $37M | $24M | $0 | $0 | $9.0K | |
| Net Stock Activity | $17M | $31M | $9M | $0 | $0 | $86M | $50M | · | $24M | $0 | $0 | $9.0K | |
| Financing Cash Flow | $28M | $61M | $8M | $-575.0K | $4M | $81M | $54M | $39M | $22M | $-490.0K | $-2M | $-611.0K | |
| Net Change in Cash | $32M | $-46M | $-49M | $-3M | $-32M | $59M | $38M | $22M | $12M | $-3M | $-3M | $4M | |
| Taxes Paid | · | $17.0K | $194.0K | $100.0K | $102.0K | $312.0K | $5.0K | $5.0K | $32.0K | $5.0K | $8.0K | $15.0K | |
| Free Cash Flow | $-24M | $-54M | $-57M | $3M | $-28M | $-20M | $-16M | $-17M | $-10M | $-4M | $-2M | $19.0K |
Kârlılık
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -59.3% | -98.6% | -97.0% | -25.2% | -21.7% | -34.6% | -18.3% | -18.6% | -45.9% | -17.5% | -18.6% | -54.1% | |
| Net Margin | -62.5% | -110.0% | -108.7% | -24.2% | -20.3% | -34.8% | -17.4% | -17.9% | -46.0% | -17.5% | -18.1% | -54.0% | |
| Pretax Margin | -62.4% | -109.9% | -108.6% | -24.0% | -20.1% | -34.3% | -17.4% | -18.0% | -45.8% | -17.6% | -18.9% | -54.7% | |
| EBITDA Margin | -51.8% | -90.3% | -97.0% | -25.2% | -21.7% | -34.6% | -18.3% | -18.6% | -45.9% | -17.5% | -18.6% | -54.1% | |
| ROA | -29.6% | -45.7% | -39.4% | -13.5% | -9.1% | -13.0% | -10.4% | -16.4% | -51.5% | -21.3% | -16.3% | -35.7% | |
| ROE | -82.8% | -93.0% | -85.6% | -22.5% | -12.8% | -18.4% | -11.5% | -19.6% | -98.6% | -40.8% | -30.8% | -56.3% | |
| ROIC | -46.1% | -61.1% | -78.7% | -24.3% | -13.9% | -14.3% | -11.9% | -20.0% | -92.8% | -44.6% | -32.5% | -71.7% |
Likidite ve Solventlik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.8 | 4.2 | 2.6 | 3.3 | 4.9 | 7.4 | 7.4 | 3.8 | 1.8 | 2.2 | 2.2 | 2.4 | |
| Quick Ratio | 3.1 | 3.1 | 2.1 | 3.0 | 4.2 | 6.5 | 6.5 | 3.6 | 1.7 | 2.0 | 2.1 | 2.2 | |
| Debt / Equity | 0.8 | 0.4 | · | · | · | · | · | · | 0.0 | · | · | · | |
| LT Debt / Equity | 0.8 | 0.4 | · | · | · | · | · | · | 0.0 | · | · | · |
Verimlilik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.4 | 0.4 | 0.6 | 0.4 | 0.4 | 0.6 | 0.9 | 1.1 | 1.2 | 0.9 | 0.7 | |
| Inventory Turnover | 5.2 | 7.3 | 5.4 | 23.9 | 20.9 | 20.6 | 32.6 | 15.5 | 15.4 | 10.7 | 5.5 | 6.7 | |
| Receivables Turnover | · | · | 3.3 | 4.9 | 5.4 | 6.0 | 6.7 | 5.3 | 5.6 | 7.4 | 7.5 | 7.6 |
Hisse Başına
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.56 | $0.82 | $1.24 | $2.20 | $2.52 | $2.65 | $1.79 | $1.03 | $0.51 | $0.46 | $0.57 | $0.67 | |
| Revenue / Share | $0.81 | $0.81 | $1.03 | $2.12 | $1.62 | · | · | · | · | · | · | · | |
| Cash Flow / Share | $-0.22 | $-0.67 | $-0.77 | $0.17 | $-0.22 | · | · | · | · | · | · | · | |
| Cash / Share | $0.56 | $0.24 | $0.93 | $1.73 | $1.79 | $2.32 | $1.54 | $0.97 | $0.65 | $0.47 | $0.58 | $0.67 | |
| EPS (TTM) | $-0.50 | $-0.89 | $-1.12 | $-0.51 | $-0.33 | $-0.40 | $-0.21 | · | · | · | · | · |
Büyüme Oranları
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 18.6% | -15.4% | -49.4% | 32.3% | 51.7% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -20.2% | -17.3% | 0.52% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 0.38% | · | · | · | · | · | · | · | · | · | · | · |
Değerleme (TTM)
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $70M | $59M | $70M | $139M | $105M | $69M | $68M | $61M | $50M | $49M | $42M | $35M | |
| Net Income TTM | $-44M | $-65M | $-76M | $-34M | $-21M | $-24M | $-12M | $-11M | $-23M | $-9M | $-8M | $-19M | |
| Market Cap | $147M | $390M | $213M | $307M | $2.04B | $1.40B | $941M | $912M | $404M | $190M | $171M | $100M | |
| Enterprise Value | $109M | $346M | · | · | · | · | · | · | $373M | · | · | · | |
| P/E | -3.3 | -5.4 | -2.7 | -9.1 | -94.8 | -54.6 | -76.1 | · | · | · | · | · | |
| P/S | 2.1 | 6.6 | 3.0 | 2.2 | 19.4 | 20.3 | 13.8 | 15.0 | 8.1 | 3.9 | 4.1 | 2.8 | |
| P/B | 2.9 | 5.8 | 2.5 | 2.1 | 12.4 | 8.2 | 8.9 | 16.2 | 16.5 | 9.9 | 7.5 | 3.8 | |
| P / Tangible Book | 3.1 | 6.1 | 2.5 | 2.2 | 12.6 | 8.4 | · | · | · | · | · | · | |
| P / Cash Flow | -7.6 | -7.9 | -4.1 | 27.2 | -142.7 | -85.2 | -75.0 | -64.7 | -46.1 | -70.3 | -394.1 | 310.6 | |
| P / FCF | -6.2 | -7.3 | -3.7 | 103.0 | -72.5 | -69.4 | -57.8 | -54.1 | -41.4 | -52.9 | -104.6 | 5247.3 | |
| EV / EBITDA | -3.0 | -6.5 | · | · | · | · | · | · | -16.2 | · | · | · | |
| EV / FCF | -4.6 | -6.4 | · | · | · | · | · | · | -38.3 | · | · | · | |
| EV / Revenue | 1.6 | 5.8 | · | · | · | · | · | · | 7.5 | · | · | · | |
| Earnings Yield | -30.7% | -18.7% | -36.7% | -10.9% | -1.1% | -1.8% | -1.3% | · | · | · | · | · |
Gelir Tablosu
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15M | $15M | $39M | $9M | $15M | $8M | $21M | $13M | $8M | $17M | $27M | $9M | $21M | $13M | $30M | $34M | |
| Cost of Revenue | $4M | $2M | $2M | $2M | $2M | $3M | $4M | $4M | $3M | $5M | $3M | $2M | $3M | $5M | $8M | $10M | |
| R&D Expense | $12M | $11M | $12M | $14M | $14M | $13M | $12M | $12M | $11M | $11M | $11M | $14M | $17M | $17M | $20M | $22M | |
| SG&A Expense | $11M | $10M | $11M | $11M | $12M | $12M | $13M | $14M | $16M | $13M | $12M | $12M | $13M | $15M | $12M | $13M | |
| Operating Expenses | $26M | $23M | $28M | $28M | $28M | $28M | $29M | $29M | $31M | $29M | $26M | $41M | $34M | $37M | $44M | $45M | |
| Operating Income | $-11M | $-8M | $11M | $-19M | $-13M | $-20M | $-7M | $-17M | $-23M | $-12M | $282.0K | $-32M | $-13M | $-24M | $-13M | $-11M | |
| Interest Income | $535.0K | $665.0K | $656.0K | $634.0K | $584.0K | $751.0K | $940.0K | $849.0K | $972.0K | $909.0K | $906.0K | $1M | $1M | $1M | $823.0K | $436.0K | |
| Other Non-op | $-1M | $-1M | $-2M | $-1M | $-984.0K | $-942.0K | $-4M | $-5M | $-985.0K | $-516.0K | $-8M | $-4M | $-9.0K | $-25.0K | $-26.0K | $216.0K | |
| Pretax Income | $-12M | $-9M | $10M | $-20M | $-13M | $-21M | $-10M | $-21M | $-23M | $-11M | $-7M | $-35M | $-12M | $-23M | $-12M | $-10M | |
| Income Tax | $10.0K | $36.0K | $18.0K | $8.0K | $10.0K | $11.0K | $4.0K | $10.0K | $10.0K | $10.0K | $35.0K | $9.0K | $9.0K | $16.0K | $151.0K | $8.0K | |
| Net Income | $-12M | $-9M | $10M | $-20M | $-13M | $-21M | $-10M | $-21M | $-23M | $-12M | $-7M | $-35M | $-12M | $-23M | $-13M | $-10M | |
| EPS (Basic) | $-0.13 | $-0.10 | $0.13 | $-0.22 | $-0.16 | $-0.25 | $-0.12 | $-0.29 | $-0.32 | $-0.16 | $-0.11 | $-0.50 | $-0.17 | $-0.34 | $-0.19 | $-0.15 | |
| EPS (Diluted) | $-0.13 | $-0.10 | $0.13 | $-0.22 | $-0.16 | $-0.25 | $-0.12 | $-0.29 | $-0.32 | $-0.16 | $-0.11 | $-0.50 | $-0.17 | $-0.34 | $-0.19 | $-0.15 | |
| Shares (Basic) | 91,053,000 | 90,768,000 | · | 90,251,000 | 85,389,000 | 82,410,000 | · | 72,032,000 | 70,376,000 | 69,854,000 | · | 69,466,000 | 67,573,000 | 65,931,000 | · | 65,426,000 | |
| Shares (Diluted) | 91,053,000 | 90,768,000 | · | 90,251,000 | 85,389,000 | 82,410,000 | · | 72,032,000 | 70,376,000 | 69,854,000 | · | 69,466,000 | 67,573,000 | 65,931,000 | · | 65,426,000 | |
| EBITDA | $-11M | · | · | $-19M | $-13M | $-19M | · | $-17M | $-23M | $-12M | · | $-32M | $-13M | $-24M | · | $-11M |
Bilanço
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $27M | $37M | $51M | $25M | $27M | $18M | $19M | $37M | $19M | $58M | $65M | $75M | $92M | $103M | $114M | $109M | |
| Short-term Investments | $28M | $29M | $27M | $33M | $40M | $41M | $54M | $53M | $55M | $27M | · | · | · | · | · | · | |
| Inventory | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $2M | |
| Prepaid Expense | $3M | $4M | $6M | $5M | $3M | $4M | $4M | $3M | $3M | $5M | · | $5M | $4M | $5M | · | $5M | |
| Other Current Assets | $500.0K | $400.0K | $500.0K | $500.0K | $100.0K | $500.0K | $500.0K | $300.0K | $900.0K | $500.0K | · | · | · | · | · | · | |
| Current Assets | $72M | $80M | $97M | $76M | $89M | $78M | $99M | $113M | $91M | $108M | · | $103M | $120M | $130M | · | $146M | |
| PP&E (Net) | $12M | $13M | $13M | $14M | $15M | $16M | $14M | $13M | $14M | $15M | · | $15M | $23M | $24M | · | $23M | |
| PP&E (Gross) | $59M | $59M | $58M | $58M | $58M | $57M | $55M | $54M | $54M | $55M | · | $54M | $66M | $65M | · | $63M | |
| Accum. Depreciation | $47M | $46M | $45M | $44M | $43M | $42M | $41M | $41M | $40M | $40M | · | $39M | $42M | $41M | · | $39M | |
| Goodwill | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $3M | $3M | $3M | $3M | |
| Other Non-current Assets | $1M | $994.0K | $883.0K | $912.0K | $950.0K | $967.0K | $1M | $2M | $2M | $1M | · | $726.0K | $498.0K | $415.0K | · | $208.0K | |
| Total Assets | $120M | $129M | $148M | $124M | $138M | $129M | $149M | $148M | $132M | $150M | · | $154M | $207M | $218M | · | $235M | |
| Accounts Payable | $3M | $2M | $2M | $2M | $1M | $6M | $3M | $4M | $4M | $3M | · | $3M | $4M | $4M | · | $3M | |
| Accrued Liabilities | $3M | $3M | $3M | $3M | $3M | $5M | $6M | $7M | $5M | $5M | · | $9M | $7M | $8M | · | $13M | |
| Current Liabilities | $24M | $15M | $25M | $18M | $15M | $21M | $24M | $35M | $31M | $29M | · | $38M | $36M | $38M | · | $32M | |
| Capital Leases | $28M | $29M | $30M | $26M | $27M | $27M | $28M | $9M | $10M | $11M | · | $13M | $35M | $37M | · | $40M | |
| Other Non-current Liabilities | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | · | $1M | $1M | $1M | · | $1M | |
| Total Liabilities | $87M | $86M | $97M | $85M | $83M | $79M | $82M | $75M | $71M | $70M | · | $63M | $83M | $92M | · | $81M | |
| Long-term Debt | $41M | $40M | $40M | $40M | $39M | $29M | · | $29M | $28M | $28M | · | · | · | · | · | · | |
| Total Debt | $41M | · | · | $40M | $39M | $29M | · | $29M | $28M | $28M | · | · | · | · | · | · | |
| Common Stock | $9.0K | $9.0K | $9.0K | $9.0K | $9.0K | $8.0K | $8.0K | $8.0K | $7.0K | $7.0K | · | $6.0K | $6.0K | $6.0K | · | $6.0K | |
| Paid-in Capital | $660M | $659M | $657M | $655M | $652M | $633M | $630M | $626M | $593M | $588M | · | $582M | $580M | $570M | · | $563M | |
| Retained Earnings | $-627M | $-615M | $-607M | $-616M | $-597M | $-583M | $-563M | $-552M | $-532M | $-509M | · | $-490M | $-455M | $-444M | · | $-409M | |
| AOCI | $-13.0K | $-11.0K | $8.0K | $12.0K | $-3.0K | $14.0K | $52.0K | $126.0K | $-23.0K | $-16.0K | · | · | · | · | · | · | |
| Stockholders' Equity | $33M | $43M | $51M | $39M | $56M | $50M | $67M | $73M | $61M | $79M | $87M | $92M | $124M | $126M | $145M | $154M | |
| Liabilities + Equity | $120M | $129M | $148M | $124M | $138M | $129M | $149M | $148M | $132M | $150M | · | $154M | $207M | $218M | · | $235M | |
| Shares Outstanding | 91,388,000 | 90,894,000 | 90,478,000 | 90,281,000 | 90,254,000 | 82,841,000 | 81,850,000 | 81,376,000 | 70,914,000 | 70,554,000 | · | 69,827,000 | 69,804,000 | 66,696,000 | · | 65,613,000 |
Nakit Akışı
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | · | · | · | · | |
| Stock-based Comp | $2M | $1M | $2M | $3M | $3M | $2M | $3M | $3M | $5M | $3M | $2M | $2M | $3M | $3M | $3M | $5M | |
| Restructuring | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | $3M | $72.0K | $72.0K | $3M | $0 | |
| Other Non-cash | · | · | · | · | · | $3M | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-10M | $-13M | $20M | $-8M | $-18M | $-14M | $-16M | $-13M | $-12M | $-8M | $-11M | $-16M | $-16M | $-9M | $5M | $20M | |
| CapEx | $898.0K | $176.0K | $520.0K | $182.0K | $3M | $1M | $2M | $1M | $395.0K | $1M | $-380.0K | $678.0K | $2M | $3M | $-33.0K | $1M | |
| Investing Cash Flow | $175.0K | $-1M | $6M | $6M | $-367.0K | $12M | $-3M | $2M | $-27M | $-29M | $1M | $-1M | $-2M | $-3M | $33.0K | $-1M | |
| Debt Issued | · | · | $0 | $0 | $10M | $0 | $0 | $0 | $0 | $30M | $0 | $0 | $0 | $0 | · | · | |
| Net Debt Issued | · | · | · | · | · | $0 | · | · | · | $30M | · | · | · | · | · | · | |
| Stock Issued | · | · | $-1.0K | $0 | · | · | $-1.0K | $31M | $0 | $0 | $0 | $0 | $7M | $2M | $0 | $0 | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | $0 | · | · | · | $2M | · | · | |
| Financing Cash Flow | $66.0K | $-14.0K | $180.0K | $-111.0K | $27M | $1M | $1M | $30M | $-197.0K | $29M | $0 | $-108.0K | $7M | $1M | $339.0K | $133.0K | |
| Net Change in Cash | $-9M | $-14M | $26M | $-1M | $8M | $-944.0K | $-18M | $19M | $-39M | $-7M | $-10M | $-18M | $-11M | $-11M | $5M | $19M | |
| Taxes Paid | · | · | · | · | · | $0 | · | · | · | $17.0K | · | · | · | · | · | · | |
| Free Cash Flow | · | · | · | · | · | $-15M | · | · | · | $-9M | · | · | · | $-12M | · | · |
Kârlılık
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -75.3% | · | · | -220.3% | -83.9% | -271.6% | · | -129.0% | -284.9% | -69.6% | · | -345.6% | -59.2% | -182.3% | · | -30.9% | |
| Net Margin | -80.5% | · | · | -228.1% | -86.6% | -274.3% | · | -160.8% | -285.2% | -67.4% | · | -376.3% | -54.0% | -174.2% | · | -29.0% | |
| Pretax Margin | -80.4% | · | · | -228.0% | -86.5% | -274.1% | · | -160.8% | -285.1% | -67.3% | · | -376.2% | -54.0% | -174.1% | · | -29.0% | |
| EBITDA Margin | -75.3% | · | · | -220.3% | -83.9% | -255.8% | · | -129.0% | -284.9% | -69.6% | · | -345.6% | -59.2% | -182.3% | · | -30.9% | |
| ROA | -9.3% | · | · | -14.4% | -9.8% | -14.9% | · | -13.6% | -13.4% | -6.3% | · | -17.9% | -5.2% | -10.0% | · | -4.3% | |
| ROE | -27.1% | · | · | -35.0% | -22.7% | -32.1% | · | -25.0% | -24.5% | -11.2% | · | -28.4% | -8.1% | -15.9% | · | -6.2% | |
| ROIC | -15.2% | · | · | -24.2% | -13.6% | -26.0% | · | -16.2% | -25.3% | -11.1% | · | -35.0% | -10.2% | -18.8% | · | -6.9% |
Likidite ve Solventlik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.1 | · | · | 4.1 | 5.8 | 3.7 | · | 3.2 | 3.0 | 3.7 | · | 2.7 | 3.4 | 3.4 | · | 4.6 | |
| Quick Ratio | 2.3 | · | · | 3.2 | 4.4 | 2.9 | · | 2.6 | 2.4 | 2.9 | · | 1.9 | 2.6 | 2.7 | · | 3.4 | |
| Debt / Equity | 1.2 | · | · | 1.0 | 0.7 | 0.6 | · | 0.4 | 0.5 | 0.4 | · | · | · | · | · | · | |
| LT Debt / Equity | 1.0 | · | · | 1.0 | 0.7 | 0.6 | · | 0.4 | 0.5 | 0.4 | · | · | · | · | · | · |
Verimlilik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | · | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.0 | 0.1 | · | 0.0 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 2.0 | · | · | 1.2 | 1.0 | 1.3 | · | 2.0 | 1.6 | 2.2 | · | 1.1 | 1.7 | 2.5 | · | 7.2 |
Hisse Başına
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.36 | · | · | $0.43 | $0.62 | $0.60 | · | $0.90 | $0.87 | $1.12 | · | $1.31 | $1.78 | $1.89 | · | $2.35 | |
| Revenue / Share | $0.16 | · | · | $0.10 | $0.18 | $0.09 | · | $0.18 | $0.11 | $0.24 | · | $0.13 | $0.32 | $0.20 | · | $0.53 | |
| Cash Flow / Share | · | · | · | · | · | $-0.17 | · | · | · | $-0.11 | · | · | · | $-0.14 | · | · | |
| Cash / Share | $0.30 | · | · | $0.28 | $0.30 | $0.22 | · | $0.46 | $0.26 | $0.82 | · | $1.07 | $1.32 | $1.54 | · | $1.66 | |
| EPS (TTM) | $-0.32 | $-0.73 | · | $-0.75 | $-0.82 | $-0.98 | · | $-0.88 | $-1.09 | $-0.94 | · | $-1.20 | $-0.85 | $-0.72 | · | $-0.47 |
Değerleme (TTM)
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $78M | $47M | · | $53M | $57M | $50M | · | $64M | $61M | $74M | · | $74M | $99M | $116M | · | $133M | |
| Net Income TTM | $-31M | $-62M | · | $-64M | $-65M | $-74M | · | $-62M | $-76M | $-65M | · | $-82M | $-57M | $-48M | · | $-31M | |
| Market Cap | $207M | · | · | $220M | $220M | $223M | · | $251M | $220M | $246M | · | $132M | $195M | $276M | · | $398M | |
| Enterprise Value | $192M | · | · | $201M | $193M | $192M | · | $189M | $175M | $189M | · | · | · | · | · | · | |
| P/E | -7.1 | -2.2 | · | -3.3 | -3.0 | -2.7 | · | -3.5 | -2.8 | -3.7 | · | -1.6 | -3.3 | -5.8 | · | -12.9 | |
| P/S | 2.7 | · | · | 4.2 | 3.9 | 4.5 | · | 3.9 | 3.6 | 3.3 | · | 1.8 | 2.0 | 2.4 | · | 3.0 | |
| P/B | 6.3 | · | · | 5.7 | 4.0 | 4.5 | · | 3.4 | 3.6 | 3.1 | · | 1.4 | 1.6 | 2.2 | · | 2.6 | |
| P / Tangible Book | 6.8 | 3.6 | · | 6.1 | 4.1 | 4.7 | · | 3.5 | 3.7 | 3.2 | · | 1.5 | 1.6 | 2.2 | · | 2.6 | |
| P / Cash Flow | · | · | · | · | · | -16.2 | · | · | · | -31.6 | · | · | · | -30.0 | · | · | |
| EV / Revenue | 2.5 | · | · | 3.8 | 3.4 | 3.9 | · | 2.9 | 2.9 | 2.5 | · | · | · | · | · | · | |
| Earnings Yield | -14.2% | -44.8% | · | -30.7% | -33.6% | -36.4% | · | -28.6% | -35.2% | -26.9% | · | -63.5% | -30.4% | -17.4% | · | -7.8% |
En son dönem solda · null değerler · olarak gösterilir
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Gelir | $70M | $59M | $70M | $139M | $105M |
| Faaliyet Kâr Marjı % | -59.3% | -98.6% | -97.0% | -25.2% | -21.7% |
| Net Gelir | $-44M | $-65M | $-76M | $-34M | $-21M |
| Seyreltilmiş Hisse Başı Kâr | $-0.50 | $-0.89 | $-1.12 | $-0.51 | $-0.33 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Borç / Öz Sermaye | 0.8 | 0.4 | · | · | · |
| Cari Oran | 3.8 | 4.2 | 2.6 | 3.3 | 4.9 |
| Cari Oran | 3.1 | 3.1 | 2.1 | 3.0 | 4.2 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | $-24M | $-54M | $-57M | $3M | $-28M |
Kurumsal Sahipler (13F) 155 dosya · $154.0M toplam · Tarih itibarıyla 30 Haziran 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Sahipler
155
Tutulan Değer
$154.0M
Yeni pozisyonlar
29
Çıkan pozisyonlar
11
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 29 (-4 önceki Ç'ye göre) | 11 (-10 önceki Ç'ye göre) | 61 (+13 önceki Ç'ye göre) | 36 (+4 önceki Ç'ye göre) | +3.0M |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| BlackRock, Inc. | $16.462.635 | 7.284.352 | 10,69% | Hisse senetleri |
| Opaleye Management Inc. | $15.334.100 | 6.785.000 | 9,96% | Hisse senetleri |
| Aberdeen Group plc | $15.300.096 | 6.769.954 | 9,94% | Hisse senetleri |
| MILLENNIUM MANAGEMENT LLC | $12.541.054 | 5.549.139 | 8,15% | Hisse senetleri |
| Telemark Asset Management, LLC | $8.692.889 | 3.846.411 | 5,65% | Hisse senetleri |
| AMERIPRISE FINANCIAL INC | $8.609.334 | 3.809.440 | 5,59% | Hisse senetleri |
| Nantahala Capital Management, LLC | $8.189.365 | 3.623.613 | 5,32% | Hisse senetleri |
| VANGUARD CAPITAL MANAGEMENT LLC | $8.174.666 | 3.617.109 | 5,31% | Hisse senetleri |
| VANGUARD GROUP INC | $8.054.714 | 4.941.542 | 5,23% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $4.887.990 | 2.162.393 | 3,17% | Hisse senetleri |
| STATE STREET CORP | $3.970.400 | 1.756.814 | 2,58% | Hisse senetleri |
| D. E. Shaw & Co., Inc. | $3.032.952 | 1.342.014 | 1,97% | Hisse senetleri |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $3.006.263 | 1.330.205 | 1,95% | Hisse senetleri |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $2.954.206 | 1.307.171 | 1,92% | Hisse senetleri |
| Assenagon Asset Management S.A. | $2.888.746 | 1.278.206 | 1,88% | Hisse senetleri |
| AQR CAPITAL MANAGEMENT LLC | $1.910.675 | 845.431 | 1,24% | Hisse senetleri |
| TWO SIGMA INVESTMENTS, LP | $1.574.314 | 696.599 | 1,02% | Hisse senetleri |
| NORTHERN TRUST CORP | $1.543.444 | 682.940 | 1,00% | Hisse senetleri |
| FRANKLIN RESOURCES INC | $1.533.726 | 678.640 | 1,00% | Hisse senetleri |
| MORGAN STANLEY | $1.467.125 | 649.170 | 0,95% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $1.313.191 | 581.058 | 0,85% | Hisse senetleri |
| Man Group plc | $1.278.240 | 565.593 | 0,83% | Hisse senetleri |
| Post Resch Tallon Group Inc. | $1.273.460 | 563.478 | 0,83% | Hisse senetleri |
| PERKINS CAPITAL MANAGEMENT INC | $1.188.986 | 526.100 | 0,77% | Hisse senetleri |
| FMR LLC | $1.081.371 | 478.483 | 0,70% | Hisse senetleri |
| GOLDMAN SACHS GROUP INC | $982.929 | 434.924 | 0,64% | Hisse senetleri |
| ALGERT GLOBAL LLC | $973.857 | 430.910 | 0,63% | Hisse senetleri |
| Nuveen, LLC | $886.524 | 392.267 | 0,58% | Hisse senetleri |
| TUDOR INVESTMENT CORP ET AL | $808.910 | 357.925 | 0,53% | Hisse senetleri |
| DIMENSIONAL FUND ADVISORS LP | $708.690 | 313.386 | 0,46% | Hisse senetleri |
| Russell Investments Group, Ltd. | $696.292 | 308.095 | 0,45% | Hisse senetleri |
| PLATINUM INVESTMENT MANAGEMENT LTD | $597.689 | 264.464 | 0,39% | Hisse senetleri |
| ROYAL BANK OF CANADA | $594.000 | 262.926 | 0,39% | Hisse senetleri |
| Potomac Capital Management, Inc. | $587.600 | 260.000 | 0,38% | Hisse senetleri |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $547.397 | 242.211 | 0,36% | Hisse senetleri |
| XTX Topco Ltd | $543.817 | 240.627 | 0,35% | Hisse senetleri |
| BANK OF AMERICA CORP /DE/ | $543.568 | 240.517 | 0,35% | Hisse senetleri |
| UBS Group AG | $542.190 | 239.907 | 0,35% | Hisse senetleri |
| Bank of New York Mellon Corp | $510.849 | 226.039 | 0,33% | Hisse senetleri |
| CITADEL ADVISORS LLC | $432.971 | 191.580 | 0,28% | Hisse senetleri |
| Invesco Ltd. | $366.732 | 162.271 | 0,24% | Hisse senetleri |
| Cubist Systematic Strategies, LLC | $359.610 | 147.381 | 0,23% | Hisse senetleri |
| BARCLAYS PLC | $350.920 | 155.274 | 0,23% | Hisse senetleri |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $334.595 | 148.051 | 0,22% | Hisse senetleri |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $284.552 | 125.908 | 0,18% | Hisse senetleri |
| STRS OHIO | $273.460 | 121.000 | 0,18% | Hisse senetleri |
| JANE STREET GROUP, LLC | $273.042 | 120.815 | 0,18% | Hisse senetleri |
| MARSHALL WACE, LLP | $264.726 | 117.135 | 0,17% | Hisse senetleri |
| Stonepine Capital Management, LLC | $247.836 | 109.662 | 0,16% | Hisse senetleri |
| RHUMBLINE ADVISERS | $233.449 | 103.301 | 0,15% | Hisse senetleri |
Aktivistler ve %5+ sahipler 3 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| John Nicols | 16 Şubat 2021 | · | İlk başvuru | Pasif yatırım | SEC |
| – I.RS. IDENTIFICATION NO. OF ABOVE PERSON RAÍZEN ENERGIA S.A., – I.RS. IDENTIFICATION NO. OF ABOVE PERSON SHELL BRAZIL HOLDING B.V., – I.RS. IDENTIFICATION NO. OF ABOVE PERSON ROYAL DUTCH SHELL PLC, – I.RS. IDENTIFICATION NO. OF ABOVE PERSON COSAN S.A. INDUSTRIA E COMÉRCIO, – I.RS. IDENTIFICATION NO. OF ABOVE PERSON COSAN INVESTIMENTOS E PARTICIPAÇÕES S.A., – I.RS. IDENTIFICATION NO. OF ABOVE PERSON COSAN LIMITED ×2 başvurular | 26 Mayıs 2015 | · | İlk başvuru | · | SEC |
| – I.RS. IDENTIFICATION NO. OF ABOVE PERSON RAIZEN ENERGIA PARTICIPA Ç Õ ES S.A., – I.RS. IDENTIFICATION NO. OF ABOVE PERSON ISPAGNAC PARTICIPA Ç Õ ES LTDA., – I.RS. IDENTIFICATION NO. OF ABOVE PERSON ROYAL DUTCH SHELL PLC, – I.RS. IDENTIFICATION NO. OF ABOVE PERSON COSAN S.A. INDUSTRIA E COM É RCIO, – I.RS. IDENTIFICATION NO. OF ABOVE PERSON COSAN LIMITED | 07 Haziran 2011 | · | İlk başvuru | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Şirket yöneticileri 44 içeriden öğrenenler · 19 yöneticiler · 22 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Alison Moore | President and CEO | 23 Şubat 2026 A | 250.506 | 0 | 2 | $-20.672 |
| Peter M Strumph | Interim President and CEO | 01 Haziran 2012 A | 60.756 | 0 | 0 | $0 |
| Alan Shaw | President and CEO | 16 Aralık 2011 S | 202.000 | 0 | 0 | $0 |
| Georgia Erbez | Chief Financial Officer and Chief Business Officer | 23 Şubat 2026 A | 66.810 | 0 | 2 | $-20.610 |
| Sriram Ryali | Chief Financial Officer | 01 Ocak 2024 A | 175.791 | 0 | 0 | $0 |
| Gordon Sangster | SVP & Chief Financial Officer | 21 Mart 2019 M | 134.453 | 0 | 0 | $0 |
| David D O'Toole | SVP & Chief Financial Officer | 04 Eylül 2013 F | 110.687 | 0 | 0 | $0 |
| Brian Paul Dowd | Interim CFO | 01 Haziran 2012 A | 28.310 | 0 | 0 | $0 |
| Robert J Lawson | SVP and CFO | 11 Mayıs 2011 P | 44.000 | 0 | 0 | $0 |
| Kevin Norrett | Chief Operating Officer | 05 Şubat 2025 A | 177.327 | 0 | 0 | $0 |
| Stefan Lutz | Chief Scientific Officer | 23 Şubat 2026 A | 130.421 | 0 | 3 | $-17.853 |
| Margaret Nell Fitzgerald | Chief Legal and Compliance Officer | 01 Ocak 2024 A | 133.770 | 0 | 0 | $0 |
| James Lalonde | SVP, R&D | 14 Mayıs 2019 M | 133.402 | 0 | 0 | $0 |
| Michael D. Aldridge | Senior Vice President, Corporate & Strategic Development | 17 Mayıs 2018 M | 0 | 0 | 0 | $0 |
| Douglas T. Sheehy | EVP, Chief Administrative Officer, General Counsel & Secretary | 05 Mart 2016 F | 247.617 | 0 | 0 | $0 |
| Matthew Tobin | SVP, Research & Development | 16 Mayıs 2013 M | 78.707 | 0 | 0 | $0 |
| David L. Anton | SVP, BioIndustrials | 10 Şubat 2013 F | 93.777 | 0 | 0 | $0 |
| Seufer-Wasserthal Peter | SVP, Pharmaceuticals | 24 Ocak 2013 A | 93.064 | 0 | 0 | $0 |
| Joseph J. Sarret | SVP and CBO | 07 Mart 2012 A | 74.000 | 0 | 0 | $0 |
| Raymond De Vre | Yönetim kurulu üyesi | 17 Haziran 2026 A | 84.811 | 0 | 2 | $-8.633 |
| Esther Martinborough | Yönetim kurulu üyesi | 17 Haziran 2026 A | 129.036 | 0 | 0 | $0 |
| Christos Richards | Yönetim kurulu üyesi | 17 Haziran 2026 A | 85.133 | 0 | 0 | $0 |
| Cynthia Collins | Yönetim kurulu üyesi | 17 Haziran 2026 A | 112.157 | 0 | 0 | $0 |
| Stephen George Dilly | Yönetim kurulu üyesi | 17 Haziran 2026 A | 727.053 | 0 | 0 | $0 |
| Rahul Singhvi | Yönetim kurulu üyesi | 17 Haziran 2026 A | 137.052 | 0 | 0 | $0 |
| David V Smith | Yönetim kurulu üyesi | 17 Haziran 2026 A | 105.705 | 0 | 0 | $0 |
| PARKER H STEWART | Yönetim kurulu üyesi | 17 Haziran 2026 A | 143.583 | 0 | 0 | $0 |
| Dennis P Wolf | Yönetim kurulu üyesi | 21 Kasım 2025 S | 138.951 | 0 | 1 | $-13.965 |
| Byron L Dorgan | Yönetim kurulu üyesi | 11 Haziran 2024 A | 223.581 | 0 | 0 | $0 |
| Jennifer Aaker | Yönetim kurulu üyesi | 13 Haziran 2023 A | 66.211 | 0 | 0 | $0 |
| John J Nicols | Yönetim kurulu üyesi | 18 Nisan 2023 M | 783.965 | 0 | 0 | $0 |
| Patrick Y Yang | Yönetim kurulu üyesi | 14 Haziran 2022 A | 53.785 | 0 | 0 | $0 |
| Bernard J Kelley | Yönetim kurulu üyesi | 10 Ağustos 2021 M | 206.136 | 0 | 0 | $0 |
| Thomas R Baruch | Yönetim kurulu üyesi | 12 Haziran 2020 S | 33.093 | 0 | 0 | $0 |
| Pam P. Cheng | Yönetim kurulu üyesi | 11 Haziran 2019 A | 69.589 | 0 | 0 | $0 |
| Kathleen Sereda Glaub | Yönetim kurulu üyesi | 11 Haziran 2019 A | 68.481 | 0 | 0 | $0 |
| Alexander Karsner | Yönetim kurulu üyesi | 02 Ocak 2014 A | 78.519 | 0 | 0 | $0 |
| Bruce A Pasternack | Yönetim kurulu üyesi | 24 Ağustos 2010 P | 10.000 | 0 | 0 | $0 |
| James R Sulat | Yönetim kurulu üyesi | 27 Nisan 2010 J | 5.957.108 | 0 | 0 | $0 |
| Opaleye Management Inc. | 10% sahip | 01 Aralık 2025 S | 179.989 | 0 | 27 | $-7.596.890 |
| Brazil Holding B.V. Shell | 10% sahip | 31 Mayıs 2011 J | 5.573.319 | 0 | 0 | $0 |
| Equilon Enterprises LLC | 10% sahip | 20 Mayıs 2011 J | 5.573.319 | 0 | 0 | $0 |
| MAXYGEN INC | 10% sahip | 14 Aralık 2010 J | 524.643 | 0 | 0 | $0 |
| Dean Ross Taylor JR | · | 07 Şubat 2023 F | 38.554 | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
ETF sahipliği 19 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,42% | 70.133 SH | 01 Ekim 2026 | Günlük |
| IWC · iShares Trust | 0,03% | 288.891 SH | 11 Eylül 2026 | Günlük |
| IBB · iShares Trust | 0,01% | 766.290 SH | 11 Eylül 2026 | Günlük |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,01% | 496.936 SH | 19 Ağustos 2026 | Günlük |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,01% | 78.444 SH | 19 Ağustos 2026 | Günlük |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,01% | 7.738 SH | 01 Ekim 2026 | Günlük |
| IWO · iShares Trust | 0,01% | 696.097 SH | 11 Eylül 2026 | Günlük |
| IWM · iShares Trust | 0,00% | 2.244.630 SH | 11 Eylül 2026 | Günlük |
| RSSL · Global X Funds | 0,00% | 41.308 NS | 31 Temmuz 2026 | N-PORT |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,00% | 71.469 SH | 01 Ekim 2026 | Günlük |
| DFAS · Dimensional ETF Trust | 0,00% | 52.788 NS | 31 Temmuz 2026 | N-PORT |
| IWV · iShares Trust | 0,00% | 17.106 SH | 03 Eylül 2026 | Günlük |
| DFAC · Dimensional ETF Trust | 0,00% | 19.277 NS | 31 Temmuz 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,00% | 1.729 NS | 31 Temmuz 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 895.869 SH | 19 Ağustos 2026 | Günlük |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 2.633.770 SH | 19 Ağustos 2026 | Günlük |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,00% | 9.454 SH | 19 Ağustos 2026 | Günlük |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 6.744 SH | 19 Ağustos 2026 | Günlük |
| IWN · iShares Trust | · | 129.318 SH | 11 Eylül 2026 | Günlük |
CDXS Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
derecelendirme · 13 analist
AL
Medyan hedef
$5.00
+267,6%
4 30,8%
Güçlü Al
6 46,2%
Al
3 23,1%
Tut
0 0,0%
Sat
0 0,0%
Güçlü Sat
12 Aylık Fiyat Hedefi
7 analist · 2026-10-01Ortalama hedef $6.14 +351,7%
← Tüm hedeflerin altında
Mevcut fiyat $1.36
Düşük$2.00
Ortalama$6.14
Yüksek$11.00
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
Mali yıl bazında, fiyatlar her şirketin son mali yıl kapanışına göredir.
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| CDXS | $147M | -3.3 | 18.6% | -62.5% | -82.8% | · |
| LAB | $495M | -6.4 | -6.2% | -87.8% | -17.6% | 49.9% |
| QSI | · | · | · | · | · | · |
| LFCR | $249M | -5.3 | 0.47% | -30.0% | -461.3% | 31.3% |
| NAUT | $247M | -4.1 | · | · | -34.9% | · |
| QTRX | $297M | -2.5 | 1.1% | -77.1% | -36.4% | 46.8% |
| SEER | · | -1.4 | 17.0% | · | · | · |
| MXCT | $166M | -3.7 | -14.5% | -135.1% | -24.6% | 81.2% |
| CSBR | $83M | -74.5 | 4.4% | -2.0% | -30.5% | · |
| HYFT | · | · | · | -89.7% | -78.9% | 58.8% |
| CIRC | · | · | · | · | · | · |
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
Sizin için önemli olan metrikleri seçin — Yukarıdaki Tam Temeller bölümündeki herhangi bir satırın yanındaki + işaretine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kaynak: SEC 10-Q dosyalandı Ağu 11, 2026